Ingvar Rydén

Ingvar Rydén is an Associate Professor at Linköping University, affiliated with the Department of Biomedical and Clinical Sciences (BKV) and the Division of Clinical Chemistry and Pharmacology (KKF). He holds the email address ingvar.ryden@liu.se and focuses on research in clinical chemistry, liver disease biomarkers, and infectious disease diagnostics. His work spans protein glycosylation analysis, hepatocellular carcinoma detection, and SARS-CoV-2 immunoassay development. Key contributions include the ACCESS-ESLD study protocol for end-stage liver disease surveillance and studies on healthcare worker SARS-CoV-2 exposure risks.

Research interests include biomarker discovery for hepatic disorders, immunology of acute phase proteins, and diagnostic platform innovations. Notable articles address α1-acid glycoprotein fucosylation in liver disease progression and the development of rapid non-invasive surveillance tools.

Rydén’s articles reflect a focus on translational research, bridging glycobiology with clinical applications in oncology and infectious diseases. His division’s collaborative projects include work on lung inflammation models and anti-inflammatory therapies, showcasing interdisciplinary expertise in clinical and basic science.